This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
November 17, 2011 2:00 PM ET
John Gilardi –VP, Corporate Communications and Investor Relations
Peer Schatz – CEO
Helge Lubenow – VP and Head of Molecular Diagnostics Business
James Mahony – Head, Regional Virology, McMaster University
Roland Sackers – CFO
Ellen Sheets – Chief Medical Officer
Stephen Little – VP, Personalized Healthcare
Veena Singh – MD, bioTheranostics
Good afternoon. If you’ll please take your seats, we’re ready to start the event. There are some seats still here in the front that are open.
I’m John Gilardi, Vice President of Corporate Communications and Investor Relations at QIAGEN. I’d like to welcome all of you to our Annual Analyst and Investor Day. We have about 50 participants here in the room in Dallas, and as you know, our event is being held here at the Annual Meeting of the Association for Molecular Pathology, or AMP.
I want to thank all of you who made the trip to be here with us in Texas, and we’d also like to thank AMP for their support and letting us hold this event here at their venue. For those of you on the webcast, I’d like to also thank you as well for joining our event, particularly those of you in Europe where it’s now evening.
A replay will be available, starting on Friday, on the “Investor Relations” section of our homepage, at www.qiagen.com, and documents for this event are also available on our website. Today, we want to provide you with insights into our business activities and, in particular, Molecular Diagnostics. But, also, we wanted to give you an opportunity to hear from some of our customers.